[go: up one dir, main page]

UY27293A1 - Uso de derivados selectivos de indirrubina como inhibidores de vegr-r - Google Patents

Uso de derivados selectivos de indirrubina como inhibidores de vegr-r

Info

Publication number
UY27293A1
UY27293A1 UY27293A UY27293A UY27293A1 UY 27293 A1 UY27293 A1 UY 27293A1 UY 27293 A UY27293 A UY 27293A UY 27293 A UY27293 A UY 27293A UY 27293 A1 UY27293 A1 UY 27293A1
Authority
UY
Uruguay
Prior art keywords
diseases
inhibitors
indirrubine
vegr
selective
Prior art date
Application number
UY27293A
Other languages
English (en)
Inventor
Rolf Jautelat
Olaf Prien
Gerhard Siemeister
Karl Heinz Thierauch
Gerhard Eisenbrand
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of UY27293A1 publication Critical patent/UY27293A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de derivados selectivos de indirrubina como inhibidores de VRGR-R para preparar un medicamento para enfermedades tales como cánceres, tumores sólidos, leucemias, enfermedades autoinmunes, como psoriasis, alopecia y esclerosis múltiple, alopecia inducida por quimioterapéuticos y mucositosis, enfermedades cardiovasculares, enfermedades infecciosas, enfermedades nefrológicas, enfermedades neurodegenerativas crónicas, enfermedades neurodegenerativas agudas, infecciones virales como por ejemplo infecciones por citomegalovirus, herpes, hepatitis B o C, y enfermedades provocadas por HIV. Los compuestos de la invención también son útiles como inhibidores de VEGFR-3 en casos de linfangiogénesis.
UY27293A 2001-05-17 2002-05-16 Uso de derivados selectivos de indirrubina como inhibidores de vegr-r UY27293A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10125763A DE10125763A1 (de) 2001-05-17 2001-05-17 Verwendung selektiver Indirubinderivate als VEGF-R Inhibitoren

Publications (1)

Publication Number Publication Date
UY27293A1 true UY27293A1 (es) 2003-02-28

Family

ID=7686282

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27293A UY27293A1 (es) 2001-05-17 2002-05-16 Uso de derivados selectivos de indirrubina como inhibidores de vegr-r

Country Status (3)

Country Link
DE (1) DE10125763A1 (es)
UY (1) UY27293A1 (es)
WO (1) WO2002092079A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050154046A1 (en) * 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
US7582670B2 (en) 2001-12-13 2009-09-01 Natrogen Therapeutics, Inc. Methods of treating an inflammatory-related disease
US8563525B2 (en) 2004-01-12 2013-10-22 Natrogen Therapeutics International, Inc. Methods of treating an inflammatory-related disease
WO2004069213A2 (en) * 2003-01-15 2004-08-19 L'oreal Cosmetic composition comprising a 2-alkylideneaminooxyacetamide
FR2849773B1 (fr) * 2003-01-15 2006-07-14 Oreal Composition capillaire contenant un 2-alkylidene aminooxy-acetamide, son utilisation pour stimuler la pousse des cheveux et/ou freiner leur chute
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
ATE547411T1 (de) 2006-12-04 2012-03-15 Jiangsu Simcere Pharmaceutical R & D Co Ltd 3-pyrrolo-cyclohexylen-2-dihydroindolinonderiva e und anwendungen davon
WO2012044577A1 (en) 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
EP2708556B1 (en) 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
CN103333161B (zh) * 2013-05-28 2015-09-30 滁州市洛达生物科技有限公司 1’-氧代靛玉红的制备和用途
AU2016205311B2 (en) 2015-01-08 2022-02-17 The Board Of Trustees Of The Leland Stanford Junior University Factors and cells that provide for induction of bone, bone marrow, and cartilage

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1079826B1 (en) * 1998-05-29 2003-03-05 CNRS, Centre National de la Recherche Scientifique Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases
CA2369670A1 (en) * 1999-04-12 2000-10-19 Gerhard Eisenbrand Indigoid bisindole derivatives
WO2000061124A2 (en) * 1999-04-12 2000-10-19 Gerhard Eisenbrand Use off cell membrane penetrating indigoid bisindole derivatives
FR2801216A1 (fr) * 1999-11-23 2001-05-25 Centre Nat Rech Scient Utilisation de derives d'indirubine pour la fabrication de medicaments
DE10053474A1 (de) * 2000-10-24 2002-05-02 Schering Ag Schwefelhaltige Indirubinderivate, deren Herstellung und Verwendung
DE10061162A1 (de) * 2000-11-30 2002-07-11 Schering Ag Aryl-substituierte Indirubinderivate, deren Herstellung und Verwendung

Also Published As

Publication number Publication date
WO2002092079A1 (de) 2002-11-21
DE10125763A1 (de) 2002-11-28

Similar Documents

Publication Publication Date Title
UY27293A1 (es) Uso de derivados selectivos de indirrubina como inhibidores de vegr-r
DK1265889T3 (da) Lægemidler imod virussygdomme
WO2005021568A3 (en) Novel tricyclic nucleosides or nucleotides as therapeutic agents
ES2104946T3 (es) Ureas ciclicas y similares utiles como inhibidores de la proteasa retrovirica.
EA200100954A1 (ru) Производные камптотецина, обладающие противоопухолевой активностью
DK0604910T3 (da) Phosphonooxymethylethere af taxanderivater
DOP2000000109A (es) Derivados de tiazolilamida
ES2184149T3 (es) Paclitaxeles 6-tio sustituidos.
WO2003037860A3 (en) Purine analogs having hsp90-inhibiting activity
UY26886A1 (es) Polimorfos de un análogo de epotilona
CY1108254T1 (el) Ενωσεις που επηρεαζουν τη γλυκοκιναση
UY26982A1 (es) Derivados de indirubina que contienen azufre, su preparación y uso
IT1136807B (it) Mezzo per collegare due pezzi di un mobile,disposti perpendicolarmente tra di loro
FI882385A0 (fi) Fosforhaltiga hmg-coa -reduktasinhibitorer, foerfarande foer framstaellning daerav och nya mellanprodukter.
DK315889D0 (da) Antivirale kombinationer, forbindelser der kan anvendes heri, og farmaceutiske praeparater med indhold af saadanne kombinationer.
SE0300034L (sv) Användning av stammar av Parapoxvirus ovis för framställning av antivirala läkemedel och läkemedel mot cancer
AR009092A1 (es) Un procedimiento para preparar 2'-fluoro-5-metil-beta-l- arabinofuranosiluridina.
FI885811A0 (fi) Nya ammoniumfoereningar, deras framstaellning och anvaendning.
IT1057372B (it) Perfezionamento nei sistemi di radiofari per la navigazione nei porti
TNSN05133A1 (en) Imidazoquinoline derivatives as adenosine a3 receptor ligands
EP0627436A4 (en) CARCINOSTATIC CONNECTIONS AND THEIR PRODUCTION.
KR950700684A (ko) 시클릭 항-종양 촉진제 화합물, 그의 조성물, 제조 방법 및 용도(Cyclic Anti-Tumor Promoter Compounds, Compositions and Methods for Production and Use)
FI850037L (fi) Tricykliska foereningar, foerfaranden foer framstaellning av dessa, saodana foereningar innehaollande kompositioner och deras anvaendning inom medicinen.
ATE250340T1 (de) 7-methylthiooxomethyl- und 7- methylthiodioxomethyl-paclitaxele
FI961105A0 (fi) Difluoristatoniviruksen vastaisia analogeja

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20141216